MA 10.02 Nab-Paclitaxel + Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+

Authors :: Duncan J. Stewart
Juergen R. Fischer
Jaafar Bennouna
Denis Talbot
Martin Reck
M. Wolfsteiner
Conrad R. Lewanski
T.J. Ong
J. Weaver
Oscar Juan Vidal
Ramaswamy Govindan
A. Ardizoni
Santiago Ponce Aix
Daniel Morgensztern
M. Cobo Dols
Pieter E. Postmus
Source :: Journal of Thoracic Oncology. 12:S1839-S1840
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: 0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Durvalumab
business.industry
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
Medicine
business
Third line treatment
Nab-paclitaxel

Full Text Access

Tools